Literature DB >> 3345722

The heterogeneity of circulating human serum erythropoietin.

J B Sherwood1, L D Carmichael, E Goldwasser.   

Abstract

The presence of more than one form of immunoreactive erythropoietin was suggested by discrepancies between the levels of immunologically detectable and biologically active erythropoietin in the sera of normal individuals and patients with end-stage renal disease. In both groups, the level of immunologically detectable hormone was significantly higher than that of bioactive hormone. Sera from end-stage renal disease patients and normal subjects were fractionated on a gel permeation column, and the immunoreactive erythropoietin in the fractions was measured by RIA. Three classes of immunoreactive erythropoietin were found in the sera: one eluting before the [125I]erythropoietin marker, one coinciding with the [125I]erythropoietin marker, and a third eluting after the labeled tracer in the region of the cytochrome c marker. The high and low mol wt components were more immunoreactive than the human urinary erythropoietin standard in the RIA. Biological activity, as determined in the in vitro rat bone marrow assay, was found only in the material eluting with the erythropoietin tracer. These studies show that immunoreactive erythropoietin in the serum consists of three components with different immunoreactivities: high and low mol wt components and a component with a mol wt similar to that of the native hormone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345722     DOI: 10.1210/endo-122-4-1472

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow.

Authors:  W Jelkmann; G Wiedemann
Journal:  Klin Wochenschr       Date:  1990-04-17

2.  Serum erythropoietin level and mortality in kidney transplant recipients.

Authors:  Miklos Z Molnar; Adam G Tabak; Ahsan Alam; Maria E Czira; Anna Rudas; Akos Ujszaszi; Gabriella Beko; Marta Novak; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-06       Impact factor: 8.237

Review 3.  Mechanisms of anemia in CKD.

Authors:  Jodie L Babitt; Herbert Y Lin
Journal:  J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 10.121

4.  Improved microbioassay for plasma erythropoietin based on CFU-E colony formation.

Authors:  S Sakata; Y Enoki
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

Review 5.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

6.  Dynamic control of oligosaccharide modification in the mammary gland: linking recombinant human erythropoietin functional analysis of transgenic mouse milk-derived hEPO.

Authors:  Deug-Nam Kwon; Hyuk Song; Jong-Yi Park; So-Young Lee; Seong-Keon Cho; Sung-Jo Kang; Joung Soon Jang; Han Geuk Seo; Jin-Hoi Kim
Journal:  Transgenic Res       Date:  2006-02       Impact factor: 2.788

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.